肺癌新辅助治疗的现状与未来展望
本文综述了肺癌新辅助治疗的多利益相关方视角。鉴于靶向治疗和免疫治疗在晚期肺癌中的成功,早期疾病应用这些药物的研究兴趣重新兴起。新辅助药物开发有独特机遇与挑战,需标准化研究设计、终点和病理缓解定义以加速知识转化。
要点
- 靶向和免疫治疗在晚期肺癌的成功推动早期新辅助研究。
- 新辅助药物开发需标准化研究设计、终点及病理缓解定义。
- 持续多利益相关方对话对设计新型诱导策略至关重要。
核心结论
- 新辅助策略有望加速早期高危肺癌患者的药物开发。
研究设计与样本
- 本文为综述,提供多利益相关方对肺癌新辅助治疗现状的视角。
主要发现
- 晚期肺癌靶向和免疫治疗的成功重新激发早期疾病研究兴趣。
- 新辅助药物开发具有独特机遇与挑战。
关键数值与推荐
- 研究设计、终点和病理缓解定义应标准化和协调以加速知识转化。
临床怎么用
- 需与所有利益相关方持续对话以设计和测试新型诱导策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.
引用
- Blumenthal GM, Bunn PA, Chaft JE, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018. PMID: 30268698. doi:10.1016/j.jtho.2018.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。